The conversation discusses hair loss treatments, with a focus on PRP, which is viewed skeptically. Minoxidil and finasteride are recommended as more effective options.
Pelage PP405 is a new hair loss treatment in trials, potentially reactivating dormant hair follicles without affecting hormones. Results are expected in February 2025, offering an alternative to minoxidil and finasteride.
The user shared progress pictures showing hair improvement from using oral finasteride and topical minoxidil between September 2023 and May 2026. Responses express amazement at the results.
PP405 updates are seen as vague and lacking substance, causing frustration among users. Some users report positive effects from using minoxidil and dutasteride, while others remain skeptical about new treatments.
The conversation discusses dosing for 1000mg Pumpkin Seed Oil tablets and compares its DHT-lowering effects to finasteride. The user considers splitting the tablets to achieve a 500mg dose.
User experienced hair loss since 16, used Fin, Minox, and Nizoral with success but stopped due to side effects. Now using Pur D'or shampoo, Rogaine foam, scalp massages, volumizing spray, and dermarolling for hair maintenance.
Discussing and researching different treatments for hair loss, including RU58841, Dutasteride, Spironolactone, Retin-A, Stemoxydine (Neogenic), Copper peptides, Superoxide Dismutase, NANO, and Eucapil.
The conversation humorously discusses using a dermaroller for hair growth, with a playful suggestion of using it on the wrist. It includes references to Minoxidil, finasteride, and RU58841 as treatments.
The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. Users are asked to share their experiences with Pyri/Koshine.
The conversation discusses impressive results from a 28-day application of a hair loss treatment. Users compare it to their experiences with Minoxidil and Dutasteride, noting excitement over the new findings.
The post discusses the user's experience with hair loss treatment RU58841, which was tested for quality and found to be 96+% pure. The conversation includes various responses, with some users questioning the safety of the product and others expressing satisfaction with the test results.
A user shared their baseline bloodwork results before starting Finasteride 1mg every other day, seeking comparison with others who have done similar tests. They are interested in any changes observed after beginning the treatment.
A user's experience with the Big 3 (minoxidil, finasteride and RU58841) hair loss treatment along with dermarolling. The dermaroller pin was 1.5mm used once per week and drew some blood but not a lot.
The conversation is about the release timeline for clinical trial results and the availability of Breezula, a hair loss treatment. The user is not comfortable buying it as a research drug from China.
Finasteride and Propecia are essentially the same, but some people may respond differently due to inactive ingredients. If cost is not an issue, Propecia is preferred due to better quality control and consistent results.
Users discussed hair loss treatments, specifically 0.1% latanoprost with melatonin, caffeine, and biotin. Other treatments mentioned include minoxidil, finasteride, RU58841, and microneedling.
Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.
Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss, with excitement around a new drug, PP405, and a reformulated oral minoxidil in trials. Concerns about cost, side effects, and long-term use are also mentioned.
The user has been using kx826 for 10 months and topical minoxidil for 2 years, reporting slow but undeniable progress in hair regrowth. They experienced side effects from finasteride and do not use it.
A user is considering a $5,295 one-year hair loss program from HairClub/Bosley, which includes treatments like finasteride, minoxidil, and a DNA test to personalize treatment. Opinions are mixed, with some suggesting cheaper alternatives like standard medications and questioning the value of the program.
The conversation is about creating a higher concentration of the newly FDA-approved hair loss treatment, Clascoterone (Winlevi), through compounding pharmacies and possibly organizing group purchases. Some users are unfamiliar with Winlevi and are asking for an explanation of the drug.
The conversation is about skepticism towards a hair serum advertised on Instagram, with users doubting its effectiveness and one sharing a personal negative experience with the product.
The conversation is about comparing the effectiveness of fluridil and clascoterone in preventing hair loss and inquiring about their use as standalone treatments. There is a question about the concentration of the fluridil brand for efficacy.
Verteporfin treatment shows promise for hair regeneration and reducing scar tissue in hair transplants. Some users plan to try verteporfin with hair transplants, and it may also be combined with PRP in future experiments.
Finasteride prescriptions in France now require an annual certificate acknowledging psychiatric and sexual risks, as the European Medicines Agency recognizes these risks. The conversation discusses the potential mental health effects of Finasteride, with some users reporting side effects and others questioning the statistical significance of these findings.
The conversation discusses the appearance and testing of RU58841 powder for hair loss treatment. Users also mention side effects of RU58841 and suggest alternatives like dutasteride and minoxidil.
Kintor Pharmaceutical's stock rise suggests potential positive news about Pyrilutamide, a topical anti-androgen. GT20029 may also compete with existing treatments like finasteride and dutasteride.